Dr. Reddy's Laboratories · NSE: DRREDDY · BSE: 500124

Q2 FY27 results · Jul–Sep 2026

Dr. Reddy's Laboratories reported revenue from operations of ₹8,697.80 crore (down 1.5% from Q2 FY26) and net profit of ₹913.20 crore (down 31.7% from Q2 FY26) for Q2 FY27 (Jul–Sep 2026), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY27	Q2 FY26	YoY	Q1 FY27	QoQ
Revenue from operations	8,697.80	8,828.30	−1.5%	8,099.80	+7.4%
Other income	156.20	323.90	−51.8%	354.70	−56.0%
Total income	8,854.00	9,152.20	−3.3%	8,454.50	+4.7%
Profit before share of associates & JVs and tax	1,235.30	1,738.50	−28.9%	552.50	+123.6%
Share of profit/(loss) of associates & JVs	(7.70)	6.30		0.80
Net profit for the period	913.20	1,336.80	−31.7%	435.60	+109.6%
Attributable to shareholders of the company	924.80	1,347.10	−31.3%	444.30	+108.1%
EPS, basic (₹)	11.10	16.18	−31.4%	5.33	+108.3%
Net margin (%)	10.5	15.1		5.4

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY27	Q2 FY26	YoY	Q1 FY27	QoQ
Revenue from operations	5,572.60	4,618.60	+20.7%	5,136.60	+8.5%
Other income	217.30	364.20	−40.3%	440.40	−50.7%
Total income	5,789.90	4,982.80	+16.2%	5,577.00	+3.8%
Profit before tax	901.30	516.30	+74.6%	497.00	+81.3%
Net profit for the period	695.80	387.30	+79.7%	404.70	+71.9%
EPS, basic (₹)	8.35	4.65	+79.6%	4.86	+71.8%
Net margin (%)	12.5	8.4		7.9

Consolidated

Filed with BSE: 23 Oct 2026, 18:47 IST
Board meeting: 23 Oct 2026
Period: 01 Jul 2026 to 30 Sep 2026
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 23 Oct 2026, 18:47 IST
Board meeting: 23 Oct 2026
Period: 01 Jul 2026 to 30 Sep 2026
Review status: Unaudited
Source: XBRL filing on BSE